Dr. Tom Colletti
The purpose of this paper is to present a perspective on the current status and future directions of focal therapy (FT) as a primary treatment option for prostate cancer (PCa).
FT for localized PCa is a rapidly evolving field. Various recent concepts – the index lesion driving prognosis, the enhanced detection of clinically-significant cancer using multi-parametric magnetic resonance imaging (mpMRI) and targeted biopsy, improved risk-stratification using novel blood/tissue biomarkers, the recognition that reducing radical treatment (RT)-related morbidity (along with reducing pathologic progression) as a clinically meaningful endpoint - have all led to a growing interest in FT. Novel FT modalities are being investigated, mostly in phase I and II studies. Recently, level I prospective randomized data comparing partial gland ablation to standard-of-care treatment became available from one study by Azzouzi, et al1. In addition, recent developments in imaging, including 7-Tesla mpMRI, functional imaging, radiomics and contrast-enhanced ultrasound show early promise. The author also discusses emerging concepts and expanding indications in patient selection for FT.
"PA963 Final Polished Draft - Daniel Park,"
Lynchburg Journal of Medical Science: Vol. 1
, Article 64.
Available at: https://digitalshowcase.lynchburg.edu/dmscjournal/vol1/iss3/64
Available when accessing via a campus IP address or logged in with a University of Lynchburg email address.
Off-campus users can also use 'Off-campus Download' button above for access.